Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug discoverer Cephalon has reported net sales of $730.1m for the second quarter ended 30 June 2011, an increase of 2%, as compared to $712.44m for the same period in 2010.
Subscribe to our email newsletter
Cephalon‘s net income was $115.19m, compared to $92.39m for the same period in the prior year.
The company’s income from operations was $148.39m for the second quarter ended 30 June 2011, as compared to $191.86m for the same period in 2010.
For the six months ended 30 June 2011 net sales were $1.47bn, compared to $1.29bn for the same period in 2010.
Net income was $326.8m for the six months ended 30 June 2011, as compared to $192.73m for the same period prior year.
For the six months ended 30 June 2011, the company’s income from operations were $324.21m, as compared to $372.64m for the same period in 2010.
Cephalon CEO Kevin Buchi said they continue to work with both US and European authorities to obtain all necessary regulatory approvals to close the transaction with Teva.